Sökning: WFRF:(Eeles Ros) >
Practical considera...
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer
-
- Gonzalez, David (författare)
- Queen's University Belfast
-
- Mateo, Joaquin (författare)
- Vall d’Hebron Institute of Oncology
-
- Stenzinger, Albrecht (författare)
- University Hospital Heidelberg
-
visa fler...
-
- Rojo, Federico (författare)
- Hospital Fundación Jiménez Díaz
-
- Shiller, Michelle (författare)
- Baylor University Medical Centre
-
- Wyatt, Alexander W. (författare)
- University of British Columbia
-
- Penault-Llorca, Frédérique (författare)
- University of Auvergne
-
Gomella, Leonard G. (författare)
-
- Eeles, Ros (författare)
- Royal Marsden NHS Foundation Trust
-
- Bjartell, Anders (författare)
- Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Urological cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments
-
visa färre...
-
(creator_code:org_t)
- 2021-02-25
- 2021
- Engelska 15 s.
-
Ingår i: Journal of Pathology: Clinical Research. - : Wiley. - 2056-4538. ; 7:4, s. 311-325
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://onlinelibrar...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib in the metastatic castration-resistant prostate cancer (mCRPC) setting signal the need to embed molecular diagnostics in the clinical pathway of patients with mCRPC to identify those who can benefit from targeted therapies. Best practice guidelines in overall biospecimen collection and processing for molecular analysis are widely available for several tumour types. However, there is no standard protocol for molecular diagnostic testing in prostate cancer. Here, we provide a series of recommendations on specimen handling, sample pre-analytics, laboratory workflow, and testing pathways to maximise the success rates for clinical genomic analysis in prostate cancer. Early involvement of a multidisciplinary team of pathologists, urologists, oncologists, radiologists, nurses, molecular scientists, and laboratory staff is key to enable optimal workflow for specimen selection and preservation at the time of diagnosis so that samples are available for molecular analysis when required. Given the improved outcome of patients with mCRPC and homologous recombination repair gene alterations who have been treated with PARP inhibitors, there is an urgent need to incorporate high-quality genomic testing in the routine clinical pathway of these patients.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- homologous recombination repair
- mCRPC
- metastatic prostate cancer
- molecular diagnostics
- poly(ADP-ribose) polymerase inhibitors
Publikations- och innehållstyp
- for (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Gonzalez, David
-
Mateo, Joaquin
-
Stenzinger, Albr ...
-
Rojo, Federico
-
Shiller, Michell ...
-
Wyatt, Alexander ...
-
visa fler...
-
Penault-Llorca, ...
-
Gomella, Leonard ...
-
Eeles, Ros
-
Bjartell, Anders
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Patho ...
- Av lärosätet
-
Lunds universitet